Twist Bioscience proposes $250M stock offering, directly challenging its self-funding thesis

What happened

Twist Bioscience announced a proposed $250 million public offering of common stock, with an option for underwriters to purchase an additional $37.5 million, just one day after filing its Q3 FY2026 10-Q showing adjusted EBITDA of negative $11.3 million, an operating loss of $36.3 million, and cash plus short-term investments down to $166.8 million. The move contradicts the investment case that the company would reach Q4 FY2026 EBITDA breakeven without tapping equity markets, as the DeepValue report explicitly identified material ATM usage before self-funding as a thesis breaker. Management had previously filed a $200 million ATM in June 2026 but had not used it; now, a larger underwritten offering signals urgent capital needs and dilution risk that the market had not fully priced.

Implication

While the raise may extend the cash runway and fund growth, it materially increases the share count and delays per-share profitability, undermining the bull case. The stock's ~$5.7B market cap and high revenue multiple depended on management avoiding dilution; this offering resets expectations, making it harder for the stock to recover to prior valuation levels until the company proves sustained profitability and cash generation—likely several quarters away.

Thesis delta

The proposed offering directly triggers the thesis breaker of material equity issuance before self-funding, invalidating the previous assumption that management would refrain from tapping the ATM. This shifts the investment case from “wait for breakeven” to a more defensive stance, requiring proof that the raised capital will lead to improved cash flow and not just cover ongoing burn.